Credits Available: 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC Points

Description: This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant, Pharmacist
Target Specialties: Oncology, Hematology/Oncology

Abhishek Tripathi

City of Hope
Associate Professor

Abhishek Tripathi, MD is an associate professor of medicine in the section of hematology/oncology. Dr. Tripathi specializes in the treatment of genitourinary cancers.
His research interests include clinical trials focusing on novel therapeutic strategies in kidney, bladder and prostate cancer. Dr. Tripathi completed medical school at the University of Delhi in New Delhi, India. He subsequently completed his Internal Medicine Residency at the University of Massachusetts Medical School followed by a hematology/oncology fellowship at the University of Massachusetts-Baystate Medical Center. During his final year of fellowship he was awarded the honor of Chief Fellow. He is board certified in internal medicine, hematology, and medical oncology.